Rare diseases
Investigational molecules
Locations
Study on Early Treatment with Teclistamab and Talquetamab for Patients with Newly Diagnosed High-Risk Multiple Myeloma
SpainStudy Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant
ItalyStudy Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant
ItalyStudy on Continuing Elotuzumab Treatment for Patients with Multiple Myeloma from Previous Trials
RomaniaStudy Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
BelgiumStudy Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant
AustriaStudy of Belantamab Mafodotin Alone and with Drug Combination for Patients with Relapsed/Refractory Multiple Myeloma
FranceStudy Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma
The NetherlandsComparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy
GermanyStudy Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant
BelgiumStudy on the Effectiveness and Safety of Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma
DenmarkStudy on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients
GermanyTell us about your condition – we search every trial in Europe and connect you with the right site.
